Abbott Laboratories (ABT) managed to stay afloat and traded higher with an addition of 0.56 point or 1.34% at $42.33. The money flow data is a negative $(-8.72) million with $62.07 million in upticks and $70.79 million in downticks. The intraday up/down ratio came in at 0.88. The shares has seen 3.24% change for the week in its share price.From the data available, it was found that a block transaction occurred during the course of trading. For it, the aggregated worth of the upticks was $12.54 million and the combined worth of the downticks was $20.81, Million, leading to the up/down ratio of 0.6. The block trade saw a net money flow of $(-8.27) million.Block trades are executed by Investment Banking firms or Wealth Managers shifting positions or Day traders taking advantage of trading signals.
Shares of Abbott Laboratories rose by 5.01% in the last five trading days and 10.92% for the last 4 weeks. Abbott Laboratories is up 8.57% in the last 3-month period. Year-to-Date the stock performance stands at 10.92%. Abbott Laboratories (NYSE:ABT) rose 1.34% or 0.56 points on Wednesday and made its way into the gainers of the day. After trading began at $41.51 the stock was seen hitting $42.37 as a peak level and $41.44 as the lowest level. The stock ended up at $42.33. The daily volume was measured at 11,948,793 shares. The 52-week high of the share price is $45.79 and the 52-week low is $36.02. The company has a market cap of $73,070 million.
Company has reported several Insider transactions to the SEC, on Dec 21, 2016, Brian J Blaser (Executive Vice President) purchased 15,580 shares at 38.44 per share price.On Dec 16, 2016, Robert B Ford (Executive Vice President) purchased 12,775 shares at 39.08 per share price.On Nov 14, 2016, Miles D White (CEO) purchased 58,263 shares at 40.65 per share price.
Abbott Laboratories Last issued its quarterly earnings results on Jan 25, 2017. The company reported $0.65 EPS for the quarter. Analyst had a consensus estimate of $0.65. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5375.38 million. The companys revenue was up 2.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.62 EPS.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Abbott Laboratories was Reiterated by RBC Capital Mkts on Jan 26, 2017 to Outperform, Lowers Price Target to $ 46 from a previous price target of $48 .
Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. They have a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals.